Archive · 2 Jul 2025
Promising Data Fuels Hope for Psychedelic Depression Treatment
Scientists are testing a new medicine for depression called BPL-003, which is like a close relative to some psychedelic drugs.
In a test, people who took a higher dose of BPL-003 felt less sad than those who took a small dose.
This is good news because it might mean this medicine can help people with depression.
Companies making similar medicines saw their stock prices go up.
Also, officials in charge of approving drugs seem to be more open to this type of treatment.
This could mean this new drug and similar ones might be approved in the future, and more people could get help for depression.
Atai Life Sciences and Beckley Psytech reported positive results for BPL-003, a nasal spray for depression.
Patients on a higher dose of BPL-003 showed an average 11.5-point decrease in depression symptoms.
The Beckley drug, BPL-003, is a nasal spray version of the psychedelic 5-MeO-DMT.
Shares of Atai Life Sciences, Compass Pathways, and MindMed increased due to the positive data.
FDA officials, including Commissioner Dr. Marty Makary, show a receptive attitude toward psychedelic therapies.
- Who
- Atai Life Sciences and Beckley Psytech.
- What
- Positive results were reported for the depression treatment BPL-003.
- When
- The results were announced on Tuesday.
- Where
- The trial took place at an unspecified location.
- Why
- To treat difficult-to-treat depression symptoms.
Potential Positives
Potential Concerns
Efficacy
Potential Positives
Improved depression symptoms in patients.
Potential Concerns
Need for further testing and FDA approval.
Regulatory Approval
Potential Positives
Positive attitude from FDA officials.
Potential Concerns
FDA needs to analyze data before approval.
- Drug Name
- BPL-003
- Drug Type
- Nasal spray
- Target Condition
- Depression
- Active Ingredient
- 5-MeO-DMT
- Atai Share Increase
- 24%
- Control Group Symptom Drop
- 5.8 points
- High Dose Symptom Drop
- 11.5 points